325 related articles for article (PubMed ID: 15637733)
1. 5-aminosalicylic acid is an attractive candidate agent for chemoprevention of colon cancer in patients with inflammatory bowel disease.
Cheng Y; Desreumaux P
World J Gastroenterol; 2005 Jan; 11(3):309-14. PubMed ID: 15637733
[TBL] [Abstract][Full Text] [Related]
2. Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis.
Qiu X; Ma J; Wang K; Zhang H
Oncotarget; 2017 Jan; 8(1):1031-1045. PubMed ID: 27906680
[TBL] [Abstract][Full Text] [Related]
3. Cancer risk and chemoprevention in Chinese inflammatory bowel disease patients: a population-based cohort study.
Mak JWY; So J; Tang W; Yip TCF; Leung WK; Li M; Lo FH; Ng KM; Sze SF; Leung CM; Tsang SWC; Shan EHS; Chan KH; Lam BCY; Hui AJ; Chow WH; Chan FKL; Ng SC
Scand J Gastroenterol; 2020 Mar; 55(3):279-286. PubMed ID: 32119788
[No Abstract] [Full Text] [Related]
4. Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: lack of efficacy against nascent adenomatous polyps in the Apc(Min) mouse.
Ritland SR; Leighton JA; Hirsch RE; Morrow JD; Weaver AL; Gendler SJ
Clin Cancer Res; 1999 Apr; 5(4):855-63. PubMed ID: 10213222
[TBL] [Abstract][Full Text] [Related]
5. 5-Aminosalicylic acid and chemoprevention: does it work?
Lopez A; Peyrin-Biroulet L
Dig Dis; 2013; 31(2):248-53. PubMed ID: 24030235
[TBL] [Abstract][Full Text] [Related]
6. 5-Aminosalicylic Acid Chemoprevention in Inflammatory Bowel Diseases: Is It Necessary in the Age of Biologics and Small Molecules?
Herfarth H; Vavricka SR
Inflamm Intest Dis; 2022 Jan; 7(1):28-35. PubMed ID: 35224015
[TBL] [Abstract][Full Text] [Related]
7. The pharmacological profile and clinical use of mesalazine (5-aminosalicylic acid).
Klotz U
Arzneimittelforschung; 2012 Feb; 62(2):53-8. PubMed ID: 22344548
[TBL] [Abstract][Full Text] [Related]
8. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease.
Terdiman JP; Steinbuch M; Blumentals WA; Ullman TA; Rubin DT
Inflamm Bowel Dis; 2007 Apr; 13(4):367-71. PubMed ID: 17206695
[TBL] [Abstract][Full Text] [Related]
9. Chemoprevention: risk reduction with medical therapy of inflammatory bowel disease.
Chan EP; Lichtenstein GR
Gastroenterol Clin North Am; 2006 Sep; 35(3):675-712. PubMed ID: 16952746
[TBL] [Abstract][Full Text] [Related]
10. Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.
Cheddani H; Dauchet L; Fumery M; Charpentier C; Marie Bouvier A; Dupas JL; Pariente B; Peyrin-Biroulet L; Savoye G; Gower-Rousseau C
Am J Gastroenterol; 2016 Oct; 111(10):1428-1436. PubMed ID: 27481308
[TBL] [Abstract][Full Text] [Related]
11. Drug insight: aminosalicylates for the treatment of IBD.
Nielsen OH; Munck LK
Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853
[TBL] [Abstract][Full Text] [Related]
12. Patients' knowledge and fear of colorectal cancer risk in inflammatory bowel disease.
Lopez A; Collet-Fenetrier B; Belle A; Peyrin-Biroulet L
J Dig Dis; 2016 Jun; 17(6):383-91. PubMed ID: 27129893
[TBL] [Abstract][Full Text] [Related]
13. [Primary chemoprevention of colorectal cancer in patients with inflammatory bowel diseases].
Ioffe AIu
Lik Sprava; 2005 Jun; (4):45-8. PubMed ID: 16158715
[TBL] [Abstract][Full Text] [Related]
14. Chemoprevention for colon cancer: new opportunities, fact or fiction?
Terhaar Sive Droste JS; Tuynman JB; Van Dullemen HM; Mulder CJ
Scand J Gastroenterol Suppl; 2006; (243):158-64. PubMed ID: 16782636
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory bowel disease as a risk factor for colorectal cancer.
Lukas M
Dig Dis; 2010; 28(4-5):619-24. PubMed ID: 21088413
[TBL] [Abstract][Full Text] [Related]
16. Comparison of outcomes of continuation/discontinuation of 5-aminosalicylic acid after initiation of anti-tumor necrosis factor-alpha therapy in patients with inflammatory bowel disease.
Choi YI; Kim TJ; Park DK; Chung JW; Kim KO; Kwon KA; Kim YJ
Int J Colorectal Dis; 2019 Oct; 34(10):1713-1721. PubMed ID: 31471699
[TBL] [Abstract][Full Text] [Related]
17. Colon-specific prodrugs of 4-aminosalicylic acid for inflammatory bowel disease.
Dhaneshwar SS
World J Gastroenterol; 2014 Apr; 20(13):3564-71. PubMed ID: 24707139
[TBL] [Abstract][Full Text] [Related]
18. Systematic review: molecular chemoprevention of colorectal malignancy by mesalazine.
Lyakhovich A; Gasche C
Aliment Pharmacol Ther; 2010 Jan; 31(2):202-9. PubMed ID: 19891667
[TBL] [Abstract][Full Text] [Related]
19. Comparative tolerability of treatments for inflammatory bowel disease.
Stein RB; Hanauer SB
Drug Saf; 2000 Nov; 23(5):429-48. PubMed ID: 11085348
[TBL] [Abstract][Full Text] [Related]
20. Chemoprevention of colorectal cancer in inflammatory bowel disease.
Subramanian V; Logan RF
Best Pract Res Clin Gastroenterol; 2011 Aug; 25(4-5):593-606. PubMed ID: 22122774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
